Neurogene Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.9 | $0.0 | — | — |
| Operating income | -$103.3 | -$82.6 | -$55.6 | -$56.5 | -$60.7 |
| Net income | -$90.4 | -$75.1 | -$36.3 | -$55.2 | -$60.7 |
| Cash Flow Statement | |||||
| Free cash flow | -$78.4 | -$71.4 | -$51.7 | -$55.1 | -$50.8 |
Shares outstanding 15.8M · Free float 58.7%
Annual filing data through FY ended December 31, 2025; float as of August 27, 2026.